{"id":"https://openalex.org/W2141674582","doi":"https://doi.org/10.1158/1078-0432.ccr-10-2317","title":"Specifically Targeting Angiopoietin-2 Inhibits Angiogenesis, Tie2-Expressing Monocyte Infiltration, and Tumor Growth","display_name":"Specifically Targeting Angiopoietin-2 Inhibits Angiogenesis, Tie2-Expressing Monocyte Infiltration, and Tumor Growth","alternate_titles":[],"publication_year":2011,"publication_date":"2011-03-01","ids":{"openalex":"https://openalex.org/W2141674582","doi":"https://doi.org/10.1158/1078-0432.ccr-10-2317","mag":"2141674582","pmid":"https://pubmed.ncbi.nlm.nih.gov/21233403"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.ccr-10-2317","doi":"https://doi.org/10.1158/1078-0432.ccr-10-2317","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-10-2317","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2141674582"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043659180","display_name":"Hanhua Huang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hanhua Huang","raw_affiliation_strings":["Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111688026","display_name":"Jing-Yu Lai","orcid":"https://orcid.org/0009-0000-3580-1690","observed_orcids":["https://orcid.org/0009-0000-3580-1690"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jing-Yu Lai","raw_affiliation_strings":["Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019293816","display_name":"Janet Do","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Janet Do","raw_affiliation_strings":["Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072747995","display_name":"Dingguo Liu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Dingguo Liu","raw_affiliation_strings":["Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065723263","display_name":"Lingna Li","orcid":"https://orcid.org/0009-0004-7840-9372","observed_orcids":["https://orcid.org/0009-0004-7840-9372"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Lingna Li","raw_affiliation_strings":["Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112723440","display_name":"Joselyn Del Rosario","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Joselyn Del Rosario","raw_affiliation_strings":["Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006910614","display_name":"Venkata Ramana Doppalapudi","orcid":"https://orcid.org/0009-0004-7594-6260","observed_orcids":["https://orcid.org/0009-0004-7594-6260"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Venkata R. Doppalapudi","raw_affiliation_strings":["Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002453971","display_name":"Steven Robert Pirie-Shepherd","orcid":"https://orcid.org/0000-0002-7173-4576","observed_orcids":["https://orcid.org/0000-0002-7173-4576"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Steven Pirie-Shepherd","raw_affiliation_strings":["Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Nancy Levin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Nancy Levin","raw_affiliation_strings":["Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111484509","display_name":"Curt W. Bradshaw","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Curt Bradshaw","raw_affiliation_strings":["Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072560640","display_name":"Gary Woodnutt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gary Woodnutt","raw_affiliation_strings":["Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008645649","display_name":"Rodney W. Lappe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Rodney Lappe","raw_affiliation_strings":["Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110621351","display_name":"Abhijit Bhat","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Abhijit Bhat","raw_affiliation_strings":["Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: CovX Research, Pfizer Inc., San Diego, California","institution_ids":["https://openalex.org/I180857899"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I180857899"],"apc_list":null,"apc_paid":null,"fwci":6.4229,"has_fulltext":false,"cited_by_count":153,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.98038779,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":100},"biblio":{"volume":"17","issue":"5","first_page":"1001","last_page":"1011"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11469","display_name":"Lymphatic System and Diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/angiopoietin-2","display_name":"angiopoietin-2","score":0.9940000176429749},{"id":"https://openalex.org/keywords/tie2-expressing-monocytes","display_name":"Tie2-expressing monocytes","score":0.7820000052452087},{"id":"https://openalex.org/keywords/tumor-angiogenesis","display_name":"tumor angiogenesis","score":0.9459999799728394},{"id":"https://openalex.org/keywords/tumor-vasculature","display_name":"tumor vasculature","score":0.7459999918937683},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.6919999718666077},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8790000081062317},{"id":"https://openalex.org/keywords/anti-angiogenic-therapy","display_name":"anti-angiogenic therapy","score":0.6629999876022339},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5690000057220459},{"id":"https://openalex.org/keywords/sunitinib","display_name":"sunitinib","score":0.7369999885559082},{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":0.8389999866485596},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9039999842643738},{"id":"https://openalex.org/keywords/irinotecan","display_name":"irinotecan","score":0.8240000009536743},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.9990000128746033}],"concepts":[{"id":"https://openalex.org/C85219853","wikidata":"https://www.wikidata.org/wiki/Q4763284","display_name":"Angiopoietin receptor","level":3,"score":0.8261832594871521},{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.6281543970108032},{"id":"https://openalex.org/C2779094623","wikidata":"https://www.wikidata.org/wiki/Q539710","display_name":"Angiopoietin","level":4,"score":0.5484973192214966},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5473327040672302},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5434539318084717},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4566747844219208},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4500638544559479},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.4348430633544922},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.33004891872406006},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.28307288885116577},{"id":"https://openalex.org/C2777025900","wikidata":"https://www.wikidata.org/wiki/Q29725","display_name":"Vascular endothelial growth factor","level":3,"score":0.24855434894561768},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.17454349994659424},{"id":"https://openalex.org/C167734588","wikidata":"https://www.wikidata.org/wiki/Q4356503","display_name":"VEGF receptors","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004797","descriptor_name":"Enzyme-Linked Immunosorbent Assay","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008264","descriptor_name":"Macrophages","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009000","descriptor_name":"Monocytes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009374","descriptor_name":"Neoplasms, Experimental","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009374","descriptor_name":"Neoplasms, Experimental","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D009389","descriptor_name":"Neovascularization, Pathologic","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015870","descriptor_name":"Gene Expression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017207","descriptor_name":"Rats, Sprague-Dawley","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018796","descriptor_name":"Immunoconjugates","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D018796","descriptor_name":"Immunoconjugates","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D018796","descriptor_name":"Immunoconjugates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D019408","descriptor_name":"Platelet Endothelial Cell Adhesion Molecule-1","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D020794","descriptor_name":"Receptor Protein-Tyrosine Kinases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D020794","descriptor_name":"Receptor Protein-Tyrosine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D039481","descriptor_name":"CD11b Antigen","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D042702","descriptor_name":"Angiopoietin-2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D042702","descriptor_name":"Angiopoietin-2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D042787","descriptor_name":"Receptor, TIE-2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.ccr-10-2317","doi":"https://doi.org/10.1158/1078-0432.ccr-10-2317","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-10-2317","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},{"id":"pmid:21233403","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21233403","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":43,"referenced_works":["https://openalex.org/W1963667977","https://openalex.org/W1974218755","https://openalex.org/W1976019207","https://openalex.org/W1977924667","https://openalex.org/W1985317418","https://openalex.org/W1996480660","https://openalex.org/W1996859043","https://openalex.org/W1998485988","https://openalex.org/W1999099046","https://openalex.org/W2003788548","https://openalex.org/W2022066554","https://openalex.org/W2027618449","https://openalex.org/W2034269086","https://openalex.org/W2037157001","https://openalex.org/W2046475737","https://openalex.org/W2055220513","https://openalex.org/W2058170218","https://openalex.org/W2059108446","https://openalex.org/W2078429303","https://openalex.org/W2078481843","https://openalex.org/W2078532784","https://openalex.org/W2079410628","https://openalex.org/W2080162976","https://openalex.org/W2081596239","https://openalex.org/W2085052037","https://openalex.org/W2095113109","https://openalex.org/W2096508282","https://openalex.org/W2103578762","https://openalex.org/W2106570355","https://openalex.org/W2120621109","https://openalex.org/W2122927195","https://openalex.org/W2124109795","https://openalex.org/W2137812597","https://openalex.org/W2138687800","https://openalex.org/W2139866287","https://openalex.org/W2159755902","https://openalex.org/W2164122959","https://openalex.org/W2166215138","https://openalex.org/W2243079953","https://openalex.org/W2249743161","https://openalex.org/W2340612818","https://openalex.org/W3144819422","https://openalex.org/W4298213432"],"related_works":["https://openalex.org/W2047340911","https://openalex.org/W1996859043","https://openalex.org/W1998564537","https://openalex.org/W2170000965","https://openalex.org/W2521128555","https://openalex.org/W2119468857","https://openalex.org/W2108360509","https://openalex.org/W2936939933","https://openalex.org/W2145441158","https://openalex.org/W2029658107"],"abstract_inverted_index":{"PURPOSE:":[0],"Angiopoietin-1":[1],"(Ang1)":[2],"plays":[3],"a":[4,13,31,43,59,62,152],"key":[5],"role":[6],"in":[7,12,81,98,104,243],"maintaining":[8],"stable":[9],"vasculature,":[10,124],"whereas":[11,181],"tumor":[14,99,123,158,182],"Ang2":[15,29,86,119,132,168,208,233],"antagonizes":[16],"Ang1's":[17],"function":[18],"and":[19,40,61,84,92,125,188,242],"promotes":[20],"the":[21,24,38,136,227],"initiation":[22],"of":[23,42,46,58,108,230],"angiogenic":[25],"switch.":[26],"Specifically":[27],"targeting":[28],"is":[30],"promising":[32],"anticancer":[33],"strategy.":[34],"Here":[35],"we":[36],"describe":[37],"development":[39],"characterization":[41],"new":[44],"class":[45],"biotherapeutics":[47],"referred":[48],"to":[49,225],"as":[50,239],"CovX-Bodies,":[51],"which":[52],"are":[53],"created":[54],"by":[55,173],"chemical":[56],"fusion":[57],"peptide":[60],"carrier":[63],"antibody":[64],"scaffold.":[65],"EXPERIMENTAL":[66],"DESIGN:":[67],"Various":[68],"linker":[69],"tethering":[70],"sites":[71],"on":[72,79],"peptides":[73],"were":[74,96,113,171,196],"examined":[75],"for":[76,115],"their":[77],"effect":[78],"CovX-Body":[80],"vitro":[82],"potency":[83],"pharmacokinetics.":[85],"CovX-Bodies":[87,133,209,220,235],"with":[88,106,143,201,245],"low":[89],"nmol/L":[90],"IC(50)s":[91],"significantly":[93,197],"improved":[94,145],"pharmacokinetics":[95,146],"tested":[97],"xenograft":[100,155],"studies":[101],"alone":[102],"or":[103,206],"combination":[105,244],"standard":[107],"care":[109],"agents.":[110,247],"Tumor":[111],"samples":[112],"analyzed":[114],"target":[116],"engagement,":[117],"via":[118],"protein":[120,169],"level,":[121],"CD31-positive":[122],"Tie2":[126],"expressing":[127],"monocyte":[128],"penetration.":[129],"RESULTS:":[130],"Bivalent":[131],"selectively":[134],"block":[135],"Ang2-Tie2":[137],"interaction":[138],"(IC(50)":[139],"<":[140,166,179,186,194,217],"1":[141],"nmol/L)":[142],"dramatically":[144],"(T(\u00bd)":[147],">":[148],"100":[149],"hours).":[150],"Using":[151],"staged":[153],"Colo-205":[154],"model,":[156],"significant":[157],"growth":[159],"inhibition":[160],"(TGI)":[161],"was":[162],"observed":[163],"(40%-63%,":[164],"P":[165,216],"0.01).":[167,218],"levels":[170],"reduced":[172],"approximately":[174],"50%":[175],"inside":[176],"tumors":[177],"(P":[178,185,193],"0.01),":[180],"microvessel":[183],"density":[184],"0.01)":[187],"intratumor":[189],"proangiogenic":[190],"Tie2(+)CD11b(+)":[191],"cells":[192],"0.05)":[195],"reduced.":[198],"When":[199],"combined":[200],"sunitinib,":[202],"sorafenib,":[203],"bevacizumab,":[204],"irinotecan,":[205],"docetaxel,":[207],"produced":[210],"even":[211],"greater":[212],"efficacy":[213],"(\u223c80%":[214],"TGI,":[215],"CONCLUSION:":[219],"provide":[221],"an":[222],"elegant":[223],"solution":[224],"overcome":[226],"pharmacokinetic-pharmacodynamic":[228],"problems":[229],"peptides.":[231],"Long-acting":[232],"specific":[234],"will":[236],"be":[237],"useful":[238],"single":[240],"agents":[241],"standard-of-care":[246]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2141674582","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":11},{"year":2020,"cited_by_count":9},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":11},{"year":2016,"cited_by_count":10},{"year":2015,"cited_by_count":18},{"year":2014,"cited_by_count":17},{"year":2013,"cited_by_count":26},{"year":2012,"cited_by_count":15}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
